A Rare Opportunity? FDA Orphan Products Head Makes The Case For More Big Pharma Investment In Rare Diseases

"Over the last 26 years, large pharmaceutical companies have missed an incredible opportunity," says Tim Coté, head of the Food & Drug Administration's Office of Orphan Product Development